Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Immunome Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Ligand Pharmaceuticals Incorporated June 5, 202695.3%
-
Ligand Pharmaceuticals Incorporated June 9, 202594.9%
-
Ligand Pharmaceuticals Incorporated June 14, 202496.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 10, 2026 | Ligand Pharmaceuticals Incorporated | Open-market sale | −257 | $247.22 | $63,536 |
| Jun 10, 2026 | Ligand Pharmaceuticals Incorporated | Open-market sale | −232 | $248.11 | $57,562 |
| Jun 10, 2026 | Ligand Pharmaceuticals Incorporated | Open-market sale | −697 | $249.53 | $173,922 |
| Jun 10, 2026 | Ligand Pharmaceuticals Incorporated | Open-market sale | −3,405 | $251.62 | $856,766 |
| Jun 5, 2026 | Ligand Pharmaceuticals Incorporated | Grant or award | +836 | — | — |
| Mar 6, 2026 | Ligand Pharmaceuticals Incorporated | Option exercise | +2,161 | $114.15 | $246,678 |
| Mar 6, 2026 | Ligand Pharmaceuticals Incorporated | Open-market sale | −2,161 | $200.76 | $433,842 |
| Nov 7, 2025 | Ligand Pharmaceuticals Incorporated | Option exercise | +2,145 | $66.13 | $141,849 |
| Nov 7, 2025 | Ligand Pharmaceuticals Incorporated | Open-market sale | −2,145 | $205.45 | $440,690 |
| Nov 7, 2025 | Ligand Pharmaceuticals Incorporated | Option exercise | +2,034 | $69.51 | $141,383 |
| Nov 7, 2025 | Ligand Pharmaceuticals Incorporated | Open-market sale | −2,034 | $205.45 | $417,885 |
| Jun 6, 2025 | Ligand Pharmaceuticals Incorporated | Grant or award | +1,209 | — | — |
| Nov 27, 2024 | Ligand Pharmaceuticals Incorporated | Option exercise | +2,406 | $52.30 | $125,834 |
| Nov 27, 2024 | Ligand Pharmaceuticals Incorporated | Open-market sale | −2,406 | $123.65 | $297,502 |
| Jun 14, 2024 | Ligand Pharmaceuticals Incorporated | Grant or award | +1,252 | — | — |
Questions about John L. Lamattina
What boards is John L. Lamattina on?
John L. Lamattina sits on the boards of Immunome Inc. and Ligand Pharmaceuticals Incorporated.
How long has John L. Lamattina served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.